From Kratom Leaf to 7-OH Tablets: How the Product Types Differ

Scroll any vendor’s site and you’ll see the word “kratom” stretched over very different things. A bag of dried ground leaf and a small compressed tablet built around 7-hydroxymitragynine can sit on the same shelf under the same brand name. They don’t share a regulatory profile. If you buy, sell or research in this category, that gap matters more than ever in late 2026, because federal regulators are drawing their line straight through it.

What is botanical kratom leaf, and what’s actually in it?

Start with the plant. Mitragyna speciosa belongs to the coffee family and grows in Thailand and the countries around it, according to NCCIH. People there have long chewed the fresh leaves or steeped them as tea. NCCIH also says research on the plant is still at an early stage.

Inside the leaf sits a group of alkaloids, and mitragynine dominates it. Its relative 7-OH is part of the mix as well, though only a sliver of it: by the FDA’s figure, under 2% of the leaf’s alkaloid content. Why does such a small share get so much attention from regulators? Because, as the FDA explains, 7-OH attaches to mu-opioid receptors with greater strength than mitragynine. So be wary of sellers who treat the two names as interchangeable.

The federal health department’s own review lands in the same place. According to the HHS analysis behind the Justice Department update of October 9, 2026, 7-OH is present in botanical kratom naturally, at comparatively low levels. Plain leaf is the baseline. Every other format gets measured against it.

Extracts concentrate the leaf, so the label has to show by how much

An extract starts with leaf material and concentrates its alkaloids. A leaf product and an extract can both say “kratom” on the front, yet their alkaloid content per gram can be very far apart.

So read the numbers, not the name. Certificates use different units from one lab to the next, which is why one conversion is worth memorizing. A result of 1% by weight is the same as 10 mg in every gram, and the same again as 10,000 ppm. Run the 7-OH ceiling HHS has proposed through that math and its 1 mg per gram becomes 0.1%, or 1,000 ppm.

Two more details trip people up. A result printed as “ND” means the amount fell under the lowest level that particular lab can detect. It doesn’t prove the amount is zero. And a certificate borrows all of its credibility from whoever ran the test. Testing labs earn accreditation under ISO/IEC 17025, so ask whether the lab on the certificate holds it, and treat silence on that question as an answer.

Why are 7-OH tablets treated as a separate category?

Products marketed around 7-OH usually aren’t leaf with a new label on the bag. A forensic reference sheet from Cayman Chemical lays out the chemistry: mitragynine can be pulled from the leaf as an isolate, then turned into 7-OH by synthetic conversion. That conversion is how a product can end up carrying 7-OH at levels the leaf doesn’t naturally reach.

Regulators have said as much. The DEA’s July 1, 2026 announcement of its first notices of intent took aim at synthesized and concentrated products, and it carved out botanical kratom whose natural 7-OH stays under the threshold. The FDA draws a similar line. It warned seven companies in 2025 over illegal 7-OH distribution, and it describes its focus as 7-OH, not natural kratom leaf.

Branding can mislead in another way. Forensic chemists at CFSRE, the Center for Forensic Science Research and Education, have turned up MGM-15, also called dihydro-7-hydroxy mitragynine, in products carrying many different brand and blend names. A tablet’s front label doesn’t reliably tell you which compound is inside. Only a full lab report can.

Where do these products stand under federal law right now?

Federally, 7-OH remains unscheduled as of mid-October 2026. The Justice Department’s October 9 update confirmed that no temporary scheduling order for 7-OH has been issued. Instead, the DEA plans a fresh notice of intent, this time covering both 7-OH and MGPI (mitragynine pseudoindoxyl), drawing on updated HHS science and opening a new 30-day notice period.

For tablets, the part to study is the pair of tests HHS proposed, and they aren’t final. A solid product would cross the line once 7-OH and MGPI pass 1 mg per gram, whether each is measured alone or the two are summed. Liquids face the same limit per mL. The second test fails anything whose mitragynine content is under 100 times its 7-OH or MGPI content.

MGPI is already controlled. A Federal Register notice dated August 26, 2026 moved it into temporary Schedule I alongside MGM-15 and MGM-16. The leaf, by contrast, sits on no federal schedule, though NCCIH reports the DEA has labeled kratom a “drug of concern.” On the health side, the FDA has approved no kratom drug product. It also warns consumers against kratom altogether. Liver toxicity and substance use disorder are among the risks it cites.

States can go further, and some have. Tennessee’s statewide ban began on July 1, 2026. In California, the Department of Public Health has declared it illegal to make or sell kratom and 7-OH products for people to consume. Across the country, a January 2026 count by the Legislative Analysis and Public Policy Association found 30 states, plus DC, with kratom rules of some kind.

How should you compare 7-OH kratom tablets with leaf and extract listings?

If you’re already comparing products, start with documentation. The listing worth your attention is the one that tells you what you’d actually receive and whether it can legally reach you.

Match the lab report to the batch

A certificate of analysis should name the product and a batch or lot number that matches the package. If the lab isn’t named, or you can’t find its accreditation, treat the report as marketing material.

Run the two proposed tests yourself

Turn the 7-OH result into milligrams per gram, then hold it up against the ceiling HHS has proposed. Then find the mitragynine figure and work out how many times larger it is. You’re reading these numbers for legal exposure only, which is exactly how regulators will read them.

Look for a full ingredient panel

Labeling mandates exist in some states, a Congressional Research Service legal sidebar notes. Georgia and Oklahoma go as far as requiring ingredients to be listed. Even where nobody requires one, a tablet sold without an ingredient panel is a reason to move on, given what CFSRE has found in branded blends.

When you look at a store category of 7-OH kratom tablets, run those checks on each listing rather than trusting the category name. A category groups a format. It doesn’t verify each product or tell you what your state allows. Any legitimate seller should also put a 21+ age gate in front of these products.

What does browsing a full catalog show you that one category can’t?

Looking across a retailer’s whole range of 7-OH products gives you a different kind of signal. You can see whether lab documentation is presented the same way for every format, or only for a few headline items. Inconsistency across a catalog tells you more about a seller’s process than any single polished product page.

This approach has a limit. A certificate of analysis is a snapshot of one batch tested by one lab, and you can’t independently confirm that the package in your hands came from that batch. Mislabeling also happens outside the kratom aisle entirely. Utah showed this in July 2026, when its agriculture regulators, working with the state’s poison control center, flagged cat’s claw tablets sold as Buzzers, after kratom alkaloids turned up in them. Utah also bans kratom-derived synthetic compounds outright and limits how much 7-OH a product may contain.

Concentration, not the product name, is what regulators are sorting by

I’d put it plainly: if a tablet listing can’t show you the 7-OH content per gram alongside the mitragynine ratio for the batch you’d receive, treat it as unverified, whatever brand is printed on it. Tablets deserve a close look, because the proposed federal thresholds target concentrated and synthesized 7-OH products, and DEA names tablets among the forms those products take.

But the rules aren’t settled yet. The DEA’s new notice will set the next step, and its details could still shift before anything becomes final. When it’s published, go to the Federal Register text rather than a vendor’s recap of it. And before your next order, confirm what your own state currently allows.